For a minority of individuals predisposed to an allergic reaction, the previous exposure to murine anti-B7H3 therapy in cycle 1 may “prime” or sensitize them by stimulating the production of IgE antibodies, which attach to mast cells and basophils resulting in an allergic reaction. Here, IGHE is linked to allergic disease.